"The implementation of a large-scale federal vitamin D screening campaign proved to be feasible and resulted in high levels of satisfaction among both patients and providers. The findings indicated significantly low vitamin D levels among participants. Pharmacists expressed a desire for an expansion of clinical pharmacy services in the future.Vitamin D testing in pharmacies: results of a federal screening campaign."

"Blood levels of sST2 show a clinically diagnostic and prognostic value in sepsis. Further, sST2 shows a similar predictive ability as the SOFA and APACHE II scores in determining the prognosis of sepsis patients. However, sST2 has a higher predictive ability than lactic acid levels in determining prognosis in sepsis."

"This study shows that the point-of-care (POC) test AFIAS-1 can serve as an alternative to laboratory-based assays. In addition the data imply that better standardization of TSH measurements is needed."

"This study showed a higher seroprevalence rate than other studies as it was conducted toward the end of the first wave of the COVID-19 pandemic. However, we are still far from achieving herd immunity. Furthermore, strict compliance with preventive measures is the only way to ensure safety until an effective vaccine is developed."

"Different contrast media may cause false negatives in cTnI and Nt-proBNP. The contrast medium that causes the least interference should be preferred. The results of samples taken in the first hour after contrast imaging should be interpreted with care."

"PCT could support and predict the unfavorable prognosis of sepsis based on SEPSIS-3, whereas diagnostic potential of PCT requires further evaluations."

"Clinical performance of the POC D-dimer devices [Exdia TRF Plus, AFIAS-1, Standard F200, LumiraDx™ and Hipro AFS/1®] for predicting a VTE in low-risk patients was comparable to that of a laboratory-based assay. However, our results indicate that the finger stick feature of certain devices should be further improved."

"Our results show that most POC D-dimer test systems [Nano-Checker 710®, AFIAS-1®; iChroma-II®; Standard F200® and Hipro AFS/1®] perform adequately when compared with the STA-Liatest PLUS assay, especially when we take due account of results in the clinically relevant area. Only the Nano-Checker 710 test system did not fulfill the desired analytical specifications. Based upon these results and user-friendliness findings, these novel POC D-dimer assays have the potential to function as an alternative for a laboratory assay, although further studies are needed on diagnostic accuracy − to be verified on capillary samples − in the specific clinical setting where the POC devices are to be used. The Standard F200 assay demonstrated the best overall analytical performance and the Hipro AFS/1 assay proved to be the most user-friendly test system. All portable test systems evaluated possess the desired functionalities for out-of-hospital settings, combining multi-test analysis and low-volume capillary blood sampling with strongly reduced processing times."

"Afias-10 and i-Track10 are suitable for TNFi monitoring but are not interchangeable with ELISA. Consistent assay methods should be used for patient monitoring to ensure accuracy and reliability."

"In conclusion, comparing AFIAS-1® and AFIAS-10® (Boditech & Menarini) results versus LC-MS/MS gold standard, they showed acceptable good agreement, both on fresh and frozen plasma samples, with a lower, but non-clinically relevant, overestimation, particularly for AFIAS-10®, at very high levels of 25-OH-VD. In the most sensitive and clinically relevant range (between 10 and 35 ng/mL), we have observed a good statistical correlation between AFIAS-1® and AFIAS-10® results versus LC-MS/MS analyses."

"AFIAS IFX, a novel fluorescence-based lateral flow assay, exhibited excellent performance in analyzing IFX trough levels and is a potentially powerful tool for therapeutic drug monitoring in clinical settings, with opportunities for further development."

"The novel PCT assay on AFIAS-6© is an acceptable POC alternative for the diagnosis and management of sepsis at EDs to improve the flow of patients, as results are consistent with those of the standard PCT Kryptor Compact Plus© assay, despite its higher imprecision."

"This study demonstrated that the POC-AFIAS assay provides comparable results to established ELISA techniques for quantifying serum concentrations of ustekinumab, particularly within the therapeutic range. The findings suggest that the POC-AFIAS assay offers a rapid and effective tool for managing ustekinumab therapy in clinical practice."

"In conclusion, comparing AFIAS-1® and AFIAS-10® (Boditech & Menarini) results versus LC-MS/MS gold standard, they showed acceptable good agreement, both on fresh and frozen plasma samples, with a lower, but non-clinically relevant, overestimation, particularly for AFIAS-10®, at very high levels of 25-OH-VD. In the most sensitive and clinically relevant range (between 10 and 35 ng/mL), we have observed a good statistical correlation between AFIAS-1® and AFIAS-10® results versus LC-MS/MS analyses."

"The AFIAS-10 POC assay demonstrated good correlation and concordance with the ELISA method for the quantification of IFX and ADA, as well as for detecting anti-IFX and anti-ADA antibodies. However, this correlation was notably lower at higher drug concentrations."

"AFIAS IGRA-TB demonstrates comparable performance to QFT-Plus with operational advantages, suggesting it is a viable diagnostic alternative for TB infection, particularly in decentralized or resource-limited settings."